CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis

Reproductive BioMedicine Online

Volumn 20, Issue 2, 2010, Pages 286-290

  Bozdag, Gurkan ^a   Alp, Aslan ^a   Saribas, Zeynep ^a   Tuncer, Selcuk ^a   Aksu, Tarik ^a   Gurgan, Timur ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

CYP17; CYP2C19; Cytochrome p450; Endometriosis; Gene polymorphism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 17; CYTOCHROME P450 2C19; GENOMIC DNA; SEX HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; DNA SYNTHESIS; ENDOMETRIOSIS; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; MUTATIONAL ANALYSIS; OBSTETRIC PATIENT; PATIENT SELECTION; PROTEIN INTERACTION;

EID: 77649215675     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.11.007     Document Type: Article

References (28)

1. American Fertility Society, 1985. Revised American Fertility Society Classification of endometriosis: 1985. Fertil. Steril. 43, 351-352.
2. Bulun, S.E., Fang, Z., Imir, G., et al., 2004. Aromatase and endometriosis. Semi. Reprod. Med. 22, 45-50.
3. Bulun, S.E., Yang, S., Fang, Z., et al., 2002. Estrogen production and metabolism in endometriosis. Ann. N. Y. Acad. Sci. 955, 75-85, discussion 86-88, 396-406.
4. Bulun, S.E., Zeitoun, K., Takayama, K., et al., 1999. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr. Relat. Cancer 6, 293-301.
5. De Carvalho, C.V., Nogueira-De-Souza, N.C., Costa, A.M., et al., 2007. Genetic polymorphisms of cytochrome P450cl7alpha (CYP17) and progesterone receptor genes (PROGINS) in the assessment of endometriosis risk. Gynecol. Endocrinol. 23, 29-33.
6. Falconer, H., D'Hooghe, T., Fried, G., 2007. Endometriosis and genetic polymorphisms. Obstet. Gynecol. Surv. 62, 616-628.
7. Feigelson, H.S., Coetzee, G.A., Kolonel, L.N., et al., 1997. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57, 1063-1065.
8. Feigelson, H.S., McKean-Cowdin, R., Coetzee, G.A., et al., 2001. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 61, 785-789.
9. Feigelson, H.S., Shames, L.S., Pike, M.C., et al., 1998. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58, 585-587.
10. Fujita, K., Kamataki, T., 2001a. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ. Mol. Mutagen. 38, 339-346.
11. Fujita, K., Kamataki, T., 2001b. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase. Mutat. Res. 483, 35-41.
12. Goldstein, J.A., deMorais, S.M., 1994. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299.
13. Habuchi, T., Liqing, Z., Suzuki, T., et al., 2000. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60, 5710-5713.
14. Haiman, C.A., Hankinson, S.E., Spiegelman, D., et al., 1999. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 59, 1015-1020.
15. Hsieh, Y.Y., Chang, C.C., Tsai, F.J., et al., 2004. Cytochrome P450c17alpha 5′-untranslated region *T/C polymorphism in endometriosis. J. Genet. 83, 189-192.
16. Hsieh, Y.Y., Chang, C.C., Tsai, F.J., et al., 2005. Estrogen receptor alpha dinucleotide repeat and cytochrome P450c17alpha gene polymorphisms are associated with susceptibility to endometriosis. Fertil. Steril. 83, 567-572.
17. Huang, C.S., Chern, H.D., Chang, K.J., et al., 1999. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59, 4870-4875.
18. Juo, S.H., Wang, T.N., Lee, J.N., et al., 2006. CYP17, CYP1A1 and COMT polymorphisms and the risk of adenomyosis and endometriosis in Taiwanese women. Hum. Reprod. 21, 1498-1502.
19. Kado, N., Kitawaki, J., Obayashi, H., et al., 2002. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum. Reprod. 17, 897-902.
20. Kappers, W.A., Edwards, R.J., Murray, S., et al., 2001. Diazinon is activated by CYP2C19 in human liver. Toxicol. Appl. Pharmacol. 177, 68-76.
21. Kitawaki, J., Kado, N., Ishihara, H., et al., 2002. Endometriosis: the pathophysiology as an estrogen-dependent disease. J. Steroid Biochem. Mol. Biol. 83, 149-155.
22. Kitawaki, J., Obayashi, H., Ishihara, H., et al., 2001. Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum. Reprod. 16, 51-55.
23. Mitrunen, K., Hirvonen, A., 2003. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat. Res. 544, 9-41.
24. Picado-Leonard, J., Miller, W.L., 1987. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17, 20 lyase): similarity with the gene for P450c21. DNA 6, 439-448.
25. Rier, S. E., 2008. Environmental immune disruption: a comorbidity factor for reproduction? Fertil. Steril. 89, e103-e108.
26. Vietri, M.T., Cioffi, M., Sessa, M., et al., 2008. CYP17 and CYP19 gene polymorphisms in women affected with endometriosis. Fertil. Steril. 92, 1532-1535.
27. Yadav, S.S., Ruwali, M., Shah, P.P., et al., 2008. Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response. Mutat. Res. 644, 31-37.
28. Yamazaki, Y., Fujita, K., Nakayama, K., et al., 2004. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. Mutat. Res. 562, 151-162.